Frank J. Vocci

Friends Research Institute

H指数:35

被引数:4,038

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Statewide implementation of MOUD in jails: aligning barriers and strategies in the quest for acceptability and feasibility

全州范围内在监狱中实施MOUD：在追求可接受性和可行性的过程中协调障碍与策略

Health & Justice

IF2.6

2026-07-240

Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides

维持将Esmethadone归类为 investigational uncompetitive NMDAR antagonist rapid antidepressant 的原因：回复Ferré和Michaelides

Journal of Clinical Psychiatry

IF4.6

2025-12-010

PRE

Revisiting Preaddiction

JOURNAL OF ADDICTION MEDICINE

IF3.2

2024-08-100

PRE

Experience Starting an Addiction Medicine Practice-based Research Network

JOURNAL OF ADDICTION MEDICINE

IF3.2

2024-07-300

PRE

Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone'

MOLECULAR PSYCHIATRY

IF10.1

2024-05-282

OAAI

Patient Engagement in and Adaptations to Delivery of Outpatient Care for Opioid Use Disorder During the COVID-19 Pandemic

PSYCHIATRIC SERVICES

IF3.2

2024-03-011

PRE

Novel rapid-acting sublingual nicotine tablet as a cigarette substitution strategy

PSYCHOPHARMACOLOGY

IF3.3

2022-06-302

PRE

A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail

延长释放纳曲酮与延长释放丁丙诺啡的比较有效性试验的临床方案

JOURNAL OF SUBSTANCE ABUSE TREATMENT

IF4

2021-09-0112

OAAI

Addiction Medicine Practice-Based Research Network (AMNet): Building Partnerships

PSYCHIATRIC SERVICES

IF3.2

2021-07-013

Addiction Medicine Practice-Based Research Network (AMNet): Assessment Tools and Quality Measures

SUBSTANCE ABUSE AND REHABILITATION

IF5.9

2021-06-0112

OAAI

Letter to the Editor regarding: Buprenorphine for opioid use disorder: The role of public funding in its development (by Barenie and Kesselheim, 2020)

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2021-04-010

PREAI

Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials

clinical psychology science and practice

IF3.2

2020-04-2215

OAAI

Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine

clinical psychology science and practice

IF3.2

2019-12-027

OAAI

Initiating buprenorphine treatment prior to versus after release from prison: Arrest outcomes

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2018-07-0110

OAAI

A cholecystokinin B receptor antagonist and cocaine interaction, phase I study

CNS NEUROSCIENCE & THERAPEUTICS

IF5

2018-06-207

OAAI

Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry

临床实践中阿片类药物使用障碍的缓释纳曲酮 (xr-ntx): Vivitrol的成本和治疗结果注册表

ADDICTION

IF5.3

2018-04-0126

PREAI

A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2017-03-0155

OAAI

Sensitivity analysis of a comparative trial of 6 month buprenorphine implants (probuphine) and sublingual buprenorphine in stable opioid-dependent patients

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2017-02-011

PREAI

Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine A Randomized Clinical Trial

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IF55

2016-07-1991

OAAI

A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners

JOURNAL OF SUBSTANCE ABUSE TREATMENT

IF4

2015-12-0143

PREAI

Frank J. Vocci

个人简介

教育背景

工作经历

荣誉奖项

研究方向